IL132217A - Substained-release compositions and method for preparing same - Google Patents

Substained-release compositions and method for preparing same

Info

Publication number: IL132217A
Authority: IL; Israel
Prior art keywords: composition; excipient; peptide; active substance; hormone
Prior art date: 1997-04-18

Application number

IL13221798A

Other languages

English (en)

Other versions

IL132217A0 (en

Original Assignee

Ipsen Pharma Biotech

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-18

Filing date

1998-04-17

Publication date

2004-08-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26233477&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL132217(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-04-18 Priority claimed from FR9704837A external-priority patent/FR2762318B1/fr

1998-03-25 Priority claimed from FR9803666A external-priority patent/FR2776516B1/fr

1998-04-17 Application filed by Ipsen Pharma Biotech filed Critical Ipsen Pharma Biotech

2001-03-19 Publication of IL132217A0 publication Critical patent/IL132217A0/xx

2004-08-31 Publication of IL132217A publication Critical patent/IL132217A/en

Links

239000000203 mixture Substances 0.000 title claims abstract description 65
238000000034 method Methods 0.000 title description 32
239000013543 active substance Substances 0.000 claims abstract description 54
239000003094 microcapsule Substances 0.000 claims abstract description 51
229920001577 copolymer Polymers 0.000 claims abstract description 44
239000007943 implant Substances 0.000 claims abstract description 27
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 25
238000002360 preparation method Methods 0.000 claims abstract description 9
230000002035 prolonged effect Effects 0.000 claims abstract description 8
230000004927 fusion Effects 0.000 claims abstract description 3
108090000765 processed proteins & peptides Proteins 0.000 claims description 30
HPPONSCISKROOD-OYLNGHKZSA-N acetic acid;(2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-y Chemical compound CC(O)=O.C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 HPPONSCISKROOD-OYLNGHKZSA-N 0.000 claims description 25
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 25
150000003839 salts Chemical class 0.000 claims description 22
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 20
229960000434 triptorelin acetate Drugs 0.000 claims description 20
239000002253 acid Substances 0.000 claims description 18
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims description 17
108010021336 lanreotide Proteins 0.000 claims description 16
RUGAHXUZHWYHNG-NLGNTGLNSA-N acetic acid;(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5, Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 RUGAHXUZHWYHNG-NLGNTGLNSA-N 0.000 claims description 14
108090000623 proteins and genes Proteins 0.000 claims description 14
102000004169 proteins and genes Human genes 0.000 claims description 14
108010050144 Triptorelin Pamoate Proteins 0.000 claims description 12
229960001739 lanreotide acetate Drugs 0.000 claims description 12
VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 claims description 12
229960004824 triptorelin Drugs 0.000 claims description 10
239000000126 substance Substances 0.000 claims description 9
108010003422 Circulating Thymic Factor Proteins 0.000 claims description 8
DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims description 7
108010016076 Octreotide Proteins 0.000 claims description 7
230000000694 effects Effects 0.000 claims description 7
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 7
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 6
150000001875 compounds Chemical class 0.000 claims description 6
229960001494 octreotide acetate Drugs 0.000 claims description 5
PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 claims description 4
239000000275 Adrenocorticotropic Hormone Substances 0.000 claims description 4
102100033367 Appetite-regulating hormone Human genes 0.000 claims description 4
102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 4
108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 4
YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 claims description 4
102000055006 Calcitonin Human genes 0.000 claims description 4
108060001064 Calcitonin Proteins 0.000 claims description 4
108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 claims description 4
102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 claims description 4
101800001982 Cholecystokinin Proteins 0.000 claims description 4
102000011022 Chorionic Gonadotropin Human genes 0.000 claims description 4
108010062540 Chorionic Gonadotropin Proteins 0.000 claims description 4
102000007644 Colony-Stimulating Factors Human genes 0.000 claims description 4
108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 4
102400000739 Corticotropin Human genes 0.000 claims description 4
101800000414 Corticotropin Proteins 0.000 claims description 4
102000003951 Erythropoietin Human genes 0.000 claims description 4
108090000394 Erythropoietin Proteins 0.000 claims description 4
102000012673 Follicle Stimulating Hormone Human genes 0.000 claims description 4
108010079345 Follicle Stimulating Hormone Proteins 0.000 claims description 4
108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 claims description 4
102100039994 Gastric inhibitory polypeptide Human genes 0.000 claims description 4
102000004862 Gastrin releasing peptide Human genes 0.000 claims description 4
108090001053 Gastrin releasing peptide Proteins 0.000 claims description 4
102000051325 Glucagon Human genes 0.000 claims description 4
108060003199 Glucagon Proteins 0.000 claims description 4
239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims description 4
XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 claims description 4
102000009151 Luteinizing Hormone Human genes 0.000 claims description 4
108010073521 Luteinizing Hormone Proteins 0.000 claims description 4
239000000637 Melanocyte-Stimulating Hormone Substances 0.000 claims description 4
108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 claims description 4
108700020797 Parathyroid Hormone-Related Proteins 0.000 claims description 4
102000003982 Parathyroid hormone Human genes 0.000 claims description 4
108090000445 Parathyroid hormone Proteins 0.000 claims description 4
102000043299 Parathyroid hormone-related Human genes 0.000 claims description 4
108010088847 Peptide YY Proteins 0.000 claims description 4
102100029909 Peptide YY Human genes 0.000 claims description 4
102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 claims description 4
108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 claims description 4
108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 4
102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 4
102100022831 Somatoliberin Human genes 0.000 claims description 4
101710142969 Somatoliberin Proteins 0.000 claims description 4
102000011923 Thyrotropin Human genes 0.000 claims description 4
108010061174 Thyrotropin Proteins 0.000 claims description 4
239000000627 Thyrotropin-Releasing Hormone Substances 0.000 claims description 4
102400000336 Thyrotropin-releasing hormone Human genes 0.000 claims description 4
101800004623 Thyrotropin-releasing hormone Proteins 0.000 claims description 4
102000055135 Vasoactive Intestinal Peptide Human genes 0.000 claims description 4
108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims description 4
239000005557 antagonist Substances 0.000 claims description 4
229940112869 bone morphogenetic protein Drugs 0.000 claims description 4
229960004015 calcitonin Drugs 0.000 claims description 4
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 4
229960000258 corticotropin Drugs 0.000 claims description 4
229940105423 erythropoietin Drugs 0.000 claims description 4
229940028334 follicle stimulating hormone Drugs 0.000 claims description 4
108010077689 gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide Proteins 0.000 claims description 4
PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 claims description 4
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 4
229960004666 glucagon Drugs 0.000 claims description 4
229940084986 human chorionic gonadotropin Drugs 0.000 claims description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
229960002437 lanreotide Drugs 0.000 claims description 4
229940040129 luteinizing hormone Drugs 0.000 claims description 4
239000000199 parathyroid hormone Substances 0.000 claims description 4
229960001319 parathyroid hormone Drugs 0.000 claims description 4
UFTCZKMBJOPXDM-XXFCQBPRSA-N pituitary adenylate cyclase-activating polypeptide Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 UFTCZKMBJOPXDM-XXFCQBPRSA-N 0.000 claims description 4
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 4
XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 claims description 4
IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 claims description 4
229940034199 thyrotropin-releasing hormone Drugs 0.000 claims description 4
JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 claims description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 claims description 3
239000012634 fragment Substances 0.000 claims description 3
229940075620 somatostatin analogue Drugs 0.000 claims description 3
JVCXXLBLDDZMDG-SDHOMARFSA-N (2s)-2-[[(2s)-2-[[2-[[2-[[(2s)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C(=CC(O)=CC=1C)C)C1=CC=CC=C1 JVCXXLBLDDZMDG-SDHOMARFSA-N 0.000 claims description 2
LIFNDDBLJFPEAN-BPSSIEEOSA-N (2s)-4-amino-2-[[(2s)-2-[[2-[[2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H]1CCC(=O)N1 LIFNDDBLJFPEAN-BPSSIEEOSA-N 0.000 claims description 2
LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 claims description 2
102000015427 Angiotensins Human genes 0.000 claims description 2
108010064733 Angiotensins Proteins 0.000 claims description 2
108010024976 Asparaginase Proteins 0.000 claims description 2
102000015790 Asparaginase Human genes 0.000 claims description 2
108010001478 Bacitracin Proteins 0.000 claims description 2
102000013585 Bombesin Human genes 0.000 claims description 2
108010051479 Bombesin Proteins 0.000 claims description 2
101800004538 Bradykinin Proteins 0.000 claims description 2
102400000967 Bradykinin Human genes 0.000 claims description 2
108010010737 Ceruletide Proteins 0.000 claims description 2
102100025841 Cholecystokinin Human genes 0.000 claims description 2
101000904177 Clupea pallasii Gonadoliberin-1 Proteins 0.000 claims description 2
108010078777 Colistin Proteins 0.000 claims description 2
JXNRXNCCROJZFB-UHFFFAOYSA-N Di-Me ester-(2R, 3E)-Phytochromobilin Natural products NC(N)=NCCCC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 JXNRXNCCROJZFB-UHFFFAOYSA-N 0.000 claims description 2
108010065372 Dynorphins Proteins 0.000 claims description 2
108010049140 Endorphins Proteins 0.000 claims description 2
102000009025 Endorphins Human genes 0.000 claims description 2
102400000921 Gastrin Human genes 0.000 claims description 2
108010052343 Gastrins Proteins 0.000 claims description 2
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 2
108010026389 Gramicidin Proteins 0.000 claims description 2
108010051696 Growth Hormone Proteins 0.000 claims description 2
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims description 2
101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 claims description 2
101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 claims description 2
102000004877 Insulin Human genes 0.000 claims description 2
108090001061 Insulin Proteins 0.000 claims description 2
108090000467 Interferon-beta Proteins 0.000 claims description 2
102000003996 Interferon-beta Human genes 0.000 claims description 2
102000015696 Interleukins Human genes 0.000 claims description 2
108010063738 Interleukins Proteins 0.000 claims description 2
108060005987 Kallikrein Proteins 0.000 claims description 2
102000001399 Kallikrein Human genes 0.000 claims description 2
101710163560 Lamina-associated polypeptide 2, isoform alpha Proteins 0.000 claims description 2
101710189385 Lamina-associated polypeptide 2, isoforms beta/gamma Proteins 0.000 claims description 2
URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 claims description 2
102000002419 Motilin Human genes 0.000 claims description 2
101800002372 Motilin Proteins 0.000 claims description 2
108010025020 Nerve Growth Factor Proteins 0.000 claims description 2
102000015336 Nerve Growth Factor Human genes 0.000 claims description 2
102400001103 Neurotensin Human genes 0.000 claims description 2
101800001814 Neurotensin Proteins 0.000 claims description 2
102400000050 Oxytocin Human genes 0.000 claims description 2
101800000989 Oxytocin Proteins 0.000 claims description 2
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims description 2
102000007079 Peptide Fragments Human genes 0.000 claims description 2
108010033276 Peptide Fragments Proteins 0.000 claims description 2
102100029251 Phagocytosis-stimulating peptide Human genes 0.000 claims description 2
102000004576 Placental Lactogen Human genes 0.000 claims description 2
108010003044 Placental Lactogen Proteins 0.000 claims description 2
239000000381 Placental Lactogen Substances 0.000 claims description 2
102100024622 Proenkephalin-B Human genes 0.000 claims description 2
108010057464 Prolactin Proteins 0.000 claims description 2
102000003946 Prolactin Human genes 0.000 claims description 2
108010086019 Secretin Proteins 0.000 claims description 2
102100037505 Secretin Human genes 0.000 claims description 2
108010056088 Somatostatin Proteins 0.000 claims description 2
102000005157 Somatostatin Human genes 0.000 claims description 2
102100038803 Somatotropin Human genes 0.000 claims description 2
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims description 2
101710185318 Thymic factor Proteins 0.000 claims description 2
102400000159 Thymopoietin Human genes 0.000 claims description 2
239000000898 Thymopoietin Substances 0.000 claims description 2
108010046075 Thymosin Proteins 0.000 claims description 2
102000007501 Thymosin Human genes 0.000 claims description 2
108010084754 Tuftsin Proteins 0.000 claims description 2
JXNRXNCCROJZFB-RYUDHWBXSA-N Tyr-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JXNRXNCCROJZFB-RYUDHWBXSA-N 0.000 claims description 2
102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 2
108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 2
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims description 2
108010004977 Vasopressins Proteins 0.000 claims description 2
102000002852 Vasopressins Human genes 0.000 claims description 2
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims description 2
229960003272 asparaginase Drugs 0.000 claims description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims description 2
229960003071 bacitracin Drugs 0.000 claims description 2
229930184125 bacitracin Natural products 0.000 claims description 2
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 claims description 2
239000003114 blood coagulation factor Substances 0.000 claims description 2
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims description 2
229930190815 caerulein Natural products 0.000 claims description 2
YRALAIOMGQZKOW-HYAOXDFASA-N ceruletide Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(OS(O)(=O)=O)C=C1 YRALAIOMGQZKOW-HYAOXDFASA-N 0.000 claims description 2
229960001706 ceruletide Drugs 0.000 claims description 2
AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 claims description 2
229940107137 cholecystokinin Drugs 0.000 claims description 2
229960003346 colistin Drugs 0.000 claims description 2
239000002308 endothelin receptor antagonist Substances 0.000 claims description 2
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims description 2
239000002474 gonadorelin antagonist Substances 0.000 claims description 2
229960004905 gramicidin Drugs 0.000 claims description 2
ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 claims description 2
239000000122 growth hormone Substances 0.000 claims description 2
229940088597 hormone Drugs 0.000 claims description 2
239000005556 hormone Substances 0.000 claims description 2
102000058004 human PTH Human genes 0.000 claims description 2
229940125396 insulin Drugs 0.000 claims description 2
229960001388 interferon-beta Drugs 0.000 claims description 2
229940047122 interleukins Drugs 0.000 claims description 2
108010053037 kyotorphin Proteins 0.000 claims description 2
229940073475 lysozyme hydrochloride Drugs 0.000 claims description 2
CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 claims description 2
JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 claims description 2
229940053128 nerve growth factor Drugs 0.000 claims description 2
BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 claims description 2
PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 claims description 2
229960002700 octreotide Drugs 0.000 claims description 2
229960001723 oxytocin Drugs 0.000 claims description 2
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims description 2
XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 claims description 2
KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 claims description 2
108091033319 polynucleotide Proteins 0.000 claims description 2
102000040430 polynucleotide Human genes 0.000 claims description 2
239000002157 polynucleotide Substances 0.000 claims description 2
229940097325 prolactin Drugs 0.000 claims description 2
238000001243 protein synthesis Methods 0.000 claims description 2
229960002101 secretin Drugs 0.000 claims description 2
OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 claims description 2
229960000553 somatostatin Drugs 0.000 claims description 2
230000004936 stimulating effect Effects 0.000 claims description 2
YRALAIOMGQZKOW-UHFFFAOYSA-N sulfated caerulein Natural products C=1C=CC=CC=1CC(C(N)=O)NC(=O)C(CC(O)=O)NC(=O)C(CCSC)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(C(C)O)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C1NC(=O)CC1)CC1=CC=C(OS(O)(=O)=O)C=C1 YRALAIOMGQZKOW-UHFFFAOYSA-N 0.000 claims description 2
230000002992 thymic effect Effects 0.000 claims description 2
LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 claims description 2
230000014616 translation Effects 0.000 claims description 2
229940035670 tuftsin Drugs 0.000 claims description 2
IESDGNYHXIOKRW-LEOABGAYSA-N tuftsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-LEOABGAYSA-N 0.000 claims description 2
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 2
229960005356 urokinase Drugs 0.000 claims description 2
229960003726 vasopressin Drugs 0.000 claims description 2
102100025306 Integrin alpha-IIb Human genes 0.000 claims 2
101710149643 Integrin alpha-IIb Proteins 0.000 claims 2
108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
102000003390 tumor necrosis factor Human genes 0.000 claims 2
229930182470 glycoside Natural products 0.000 claims 1
150000002338 glycosides Chemical class 0.000 claims 1
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 abstract description 16
229920000642 polymer Polymers 0.000 description 52
239000000243 solution Substances 0.000 description 51
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 30
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 10
239000002245 particle Substances 0.000 description 10
238000000227 grinding Methods 0.000 description 8
238000005354 coacervation Methods 0.000 description 7
238000004108 freeze drying Methods 0.000 description 7
238000007710 freezing Methods 0.000 description 7
238000007654 immersion Methods 0.000 description 7
229910052757 nitrogen Inorganic materials 0.000 description 7
108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
230000008014 freezing Effects 0.000 description 6
239000007788 liquid Substances 0.000 description 6
102000004196 processed proteins & peptides Human genes 0.000 description 6
229920002545 silicone oil Polymers 0.000 description 6
102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
-1 acetic Chemical class 0.000 description 5
239000012528 membrane Substances 0.000 description 5
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
238000005538 encapsulation Methods 0.000 description 4
230000002209 hydrophobic effect Effects 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
238000011068 loading method Methods 0.000 description 4
239000011859 microparticle Substances 0.000 description 4
239000000523 sample Substances 0.000 description 4
238000013268 sustained release Methods 0.000 description 4
239000012730 sustained-release form Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
238000004458 analytical method Methods 0.000 description 3
229920002988 biodegradable polymer Polymers 0.000 description 3
239000004621 biodegradable polymer Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000001914 filtration Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
108010037003 Buserelin Proteins 0.000 description 2
108010069236 Goserelin Proteins 0.000 description 2
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
108010000817 Leuprolide Proteins 0.000 description 2
108091034057 RNA (poly(A)) Proteins 0.000 description 2
241000700159 Rattus Species 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
102000018594 Tumour necrosis factor Human genes 0.000 description 2
108050007852 Tumour necrosis factor Proteins 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
229960002719 buserelin Drugs 0.000 description 2
CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
238000001125 extrusion Methods 0.000 description 2
229960002913 goserelin Drugs 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
239000003999 initiator Substances 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
229960004338 leuprorelin Drugs 0.000 description 2
230000007774 longterm Effects 0.000 description 2
239000004005 microsphere Substances 0.000 description 2
229920001308 poly(aminoacid) Polymers 0.000 description 2
239000002243 precursor Substances 0.000 description 2
238000007142 ring opening reaction Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
KFWJVABDRRDUHY-XJQYZYIXSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1.C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 KFWJVABDRRDUHY-XJQYZYIXSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 1
229920002126 Acrylic acid copolymer Polymers 0.000 description 1
238000004438 BET method Methods 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 1
FOGRQMPFHUHIGU-UHFFFAOYSA-N Uridylic acid Natural products OC1C(OP(O)(O)=O)C(CO)OC1N1C(=O)NC(=O)C=C1 FOGRQMPFHUHIGU-UHFFFAOYSA-N 0.000 description 1
SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229940022663 acetate Drugs 0.000 description 1
229940081735 acetylcellulose Drugs 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
238000000889 atomisation Methods 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
239000002793 bombesin derivative Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
238000007598 dipping method Methods 0.000 description 1
LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000035558 fertility Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000012792 lyophilization process Methods 0.000 description 1
FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229920003145 methacrylic acid copolymer Polymers 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
108091005601 modified peptides Proteins 0.000 description 1
239000000178 monomer Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
239000002088 nanocapsule Substances 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
239000002077 nanosphere Substances 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000003891 oxalate salts Chemical class 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920001281 polyalkylene Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000000376 reactant Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
238000007873 sieving Methods 0.000 description 1
239000002356 single layer Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000000859 sublimation Methods 0.000 description 1
230000008022 sublimation Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
- Y10T428/2985—Solid-walled microcapsule from synthetic polymer

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Toxicology (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Immunology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Manufacturing Of Micro-Capsules (AREA)
Peptides Or Proteins (AREA)

IL13221798A 1997-04-18 1998-04-17 Substained-release compositions and method for preparing same IL132217A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR9704837A FR2762318B1 (fr)	1997-04-18	1997-04-18	Compositions presentant une liberation prolongee et leur procede de preparation
FR9803666A FR2776516B1 (fr)	1998-03-25	1998-03-25	Compositions presentant une liberation prolongee et leur procede de preparation
PCT/FR1998/000773 WO1998047489A1 (fr)	1997-04-18	1998-04-17	Compositions presentant une liberation prolongee et leur procede de preparation

Publications (2)

Publication Number	Publication Date
IL132217A0 IL132217A0 (en)	2001-03-19
IL132217A true IL132217A (en)	2004-08-31

Family

ID=26233477

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL13221798A IL132217A (en)	1997-04-18	1998-04-17	Substained-release compositions and method for preparing same

Country Status (22)

Country	Link
US (2)	US6217893B1 (de)
EP (1)	EP0980240B1 (de)
JP (1)	JP4557312B2 (de)
CN (2)	CN1313082C (de)
AR (2)	AR012448A1 (de)
AT (1)	ATE389388T1 (de)
AU (1)	AU741964B2 (de)
BR (1)	BR9808933A (de)
CA (1)	CA2286575C (de)
CZ (1)	CZ297078B6 (de)
DE (1)	DE69839264T2 (de)
DK (1)	DK0980240T3 (de)
ES (1)	ES2303353T3 (de)
HU (1)	HUP0004297A2 (de)
IL (1)	IL132217A (de)
MY (1)	MY118835A (de)
NO (2)	NO327999B1 (de)
PL (1)	PL196771B1 (de)
PT (1)	PT980240E (de)
RU (1)	RU2198678C2 (de)
TW (1)	TW577759B (de)
WO (1)	WO1998047489A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
AR012448A1 (es) *	1997-04-18	2000-10-18	Ipsen Pharma Biotech	Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
US6303138B1 (en)	1999-09-17	2001-10-16	Depuy Orthopaedics	Endothelin-based compositions for enhancing connective tissue repair
EP1274720A4 (de) *	2000-04-12	2004-08-18	Human Genome Sciences Inc	Albumin enthaltende fusionsproteine
US6824822B2 (en) *	2001-08-31	2004-11-30	Alkermes Controlled Therapeutics Inc. Ii	Residual solvent extraction method and microparticles produced thereby
CA2444518A1 (en) *	2001-04-17	2002-10-24	University Of Sheffield	Biomaterials comprising a melanocyte stimulating hormone (msh), and method of forming
WO2002097038A2 (en) *	2001-05-25	2002-12-05	Human Genome Sciences, Inc.	Chemokine beta-1 fusion proteins
KR101320817B1 (ko) *	2001-06-01	2013-10-21	노파르티스 아게	부갑상선 호르몬 및 칼시토닌의 경구 투여
CA2451187C (en)	2001-06-22	2012-08-14	Southern Biosystems, Inc.	Zero-order prolonged release coaxial implants
GB0122113D0 (en) *	2001-09-11	2001-10-31	Astrazeneca Ab	Composition
PT1463751E (pt)	2001-12-21	2013-08-26	Human Genome Sciences Inc	Proteínas de fusão de albumina
EP1463752A4 (de) *	2001-12-21	2005-07-13	Human Genome Sciences Inc	Albuminfusionsproteine
RU2252753C2 (ru) *	2002-05-15	2005-05-27	Ооо Мако	Готовая лекарственная форма инсулина человека пролонгированного действия
US20060128615A1 (en) *	2002-09-18	2006-06-15	Pierrette Gaudreau	Ghrh analogues
US20040097419A1 (en) *	2002-11-19	2004-05-20	Holger Petersen	Organic compounds
US7655618B2 (en) *	2002-12-27	2010-02-02	Diobex, Inc.	Compositions and methods for the prevention and control of insulin-induced hypoglycemia
NZ541365A (en) *	2002-12-27	2009-09-25	Diobex Inc	Compositions and methods for the prevention and control of insulin-induced hypoglycemia
CA2513213C (en)	2003-01-22	2013-07-30	Human Genome Sciences, Inc.	Albumin fusion proteins
DE04758472T1 (de) *	2003-03-26	2005-06-23	Teva Pharmaceutical Industries Ltd.	Verfahren zur herstellung eines pharmazeutischen wirkstoffs mit hochspezifischer oberfläche
WO2004089279A2 (en) *	2003-04-08	2004-10-21	Yeda Research And Development Co. Ltd.	Long-acting derivatives of pyy agonists
US20070207211A1 (en) *	2003-04-10	2007-09-06	Pr Pharmaceuticals, Inc.	Emulsion-based microparticles and methods for the production thereof
PT1615959E (pt)	2003-04-10	2013-08-29	Evonik Corp	Um método para a produção de micropartículas à base de emulsão
US7833545B2 (en) *	2003-04-29	2010-11-16	The General Hospital Corporation	Methods and devices for the sustained release of multiple drugs
WO2005009356A2 (en) *	2003-07-15	2005-02-03	Pr Pharmaceuticals, Inc.	Method for the preparation of controlled release formulations
AU2004259209A1 (en) *	2003-07-23	2005-02-03	Pr Pharmaceuticals, Inc.	Controlled release compositions
WO2005047337A1 (en) *	2003-11-13	2005-05-26	Hanmi Pharmaceutical Co., Ltd.	A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
CA2552241C (en) *	2003-12-30	2013-10-01	Durect Corporation	Co-polymeric devices for controlled release of active agents
ES2642214T3 (es) *	2004-01-21	2017-11-15	Novo Nordisk Health Care Ag	Conjugación de péptidos mediante transglutaminasa
US20060110423A1 (en) *	2004-04-15	2006-05-25	Wright Steven G	Polymer-based sustained release device
US7456254B2 (en) *	2004-04-15	2008-11-25	Alkermes, Inc.	Polymer-based sustained release device
PL2409707T3 (pl)	2004-04-15	2015-08-31	Amylin Pharmaceuticals Llc	Urządzenie o przedłużonym uwalnianiu na bazie polimeru
EP1814574A4 (de)	2004-10-27	2009-08-05	Univ Denver	Analoga des adrenocorticotropen hormons und entsprechende verfahren
EP1679065A1 (de) *	2005-01-07	2006-07-12	OctoPlus Sciences B.V.	Zubereitung mit kontrollierter Freisetzung von Interferon auf PEGT/PBT-Block-Copolymer-Basis
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
WO2006092607A1 (en) *	2005-03-02	2006-09-08	The Secretary Of State For Defence	Pharmaceutical composition
US20070106271A1 (en) *	2005-11-09	2007-05-10	Searete Llc, A Limited Liability Corporation	Remote control of substance delivery system
RU2464972C2 (ru) *	2005-12-22	2012-10-27	Новартис Аг	Композиции с замедленным высвобождением, включающие октреотид и два или более сополимера полилактида и гликолида
AU2007207618B2 (en) *	2006-01-18	2011-03-24	Foresee Pharmaceuticals Co., Ltd.	Pharmaceutical compositions with enhanced stability
EP1837014A1 (de) *	2006-03-21	2007-09-26	Hexal Ag	Subkutane Implantate welche ein abbau-resistentes Polylactid-Polymer und ein LH-RH Analogon enthalten
CA2670821C (en)	2006-08-09	2012-05-15	Intarcia Therapeutics, Inc.	Osmotic delivery systems and piston assemblies
US20080233199A1 (en) *	2007-03-22	2008-09-25	Alkermes, Inc.	Coacervation Process
CA2683610C (en)	2007-04-23	2013-01-08	Intarcia Therapeutics, Inc.	Suspension formulations of insulinotropic peptides and uses thereof
HUE031550T2 (en) *	2007-06-06	2017-07-28	Debiopharm Res & Mfg Sa	Slow release pharmaceutical composition made of microparticles
US20080317865A1 (en) *	2007-06-20	2008-12-25	Alkermes, Inc.	Quench liquids and washing systems for production of microparticles
EP2247282B1 (de) *	2008-01-30	2014-08-20	Novartis AG	Verzögert freigesetzte formulierung mit octreotid und drei linearen polyactid-co-glycolid-polymeren
WO2009102467A2 (en)	2008-02-13	2009-08-20	Intarcia Therapeutics, Inc.	Devices, formulations, and methods for delivery of multiple beneficial agents
SMT202000405T1 (it) *	2008-09-04	2020-09-10	Amylin Pharmaceuticals Llc	Formulazioni a rilascio prolungato usando veicolanti non acquosi
MX378797B (es)	2009-09-28	2025-03-10	Intarcia Therapeutics Inc	Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
USRE49251E1 (en)	2010-01-04	2022-10-18	Mapi Pharma Ltd.	Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
ES2699692T3 (es) *	2010-01-04	2019-02-12	Mapi Pharma Ltd	Sistema de depósito que comprende acetato de glatiramer
IT1402654B1 (it)	2010-09-20	2013-09-13	Cid S R L	Composizione per il rilascio di principi attivi da dispositivi di impianto
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN103163258B (zh) *	2011-12-09	2015-09-23	山东绿叶制药有限公司	一种测定痕量曲普瑞林的方法
CN102552166A (zh) *	2012-01-09	2012-07-11	北京化工大学	一种溶菌酶/聚(α-氰基丙烯酸异丁酯)载药微球的制备方法
CN104394980B (zh)	2012-03-08	2018-10-09	康斯乔最高科学研究公司	具有光致变色性质的涂层、产生所述涂层的方法及其适用于光学制品和光滑表面的用途
BR112014026957A8 (pt)	2012-05-03	2018-01-16	Janssen R&D Ireland	micropartícula, composição compreendendo a mesma, seu uso e sistema de distribuição nasal relacionados ao tratamento de infecções do trato respiratório superior
RU2506269C1 (ru) *	2012-08-03	2014-02-10	Татьяна Георгиевна Емельянова	Фармацевтическая композиция, содержащая физиологически активные гептапептиды, обладающие противосудорожным, анксиолитическим, центральным противовоспалительным и анальгетическим, а также антиалкогольным действием
JP6151848B2 (ja) *	2013-04-18	2017-06-21	シャンドンルイファーマシューティカルカンパニーリミテッド	ゴセレリン徐放性マイクロスフェア医薬組成物
CN103230624A (zh) *	2013-05-02	2013-08-07	复旦大学附属上海市第五人民医院	一种用于微创埋线治疗的植入材料
CN103720663B (zh) *	2014-01-08	2016-04-06	昆药集团股份有限公司	一种促卵泡激素缓释微球及其制备方法
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US20160106804A1 (en) *	2014-10-15	2016-04-21	Yuhua Li	Pharmaceutical composition with improved stability
CN113598842A (zh)	2015-06-03	2021-11-05	因塔西亚制药公司	植入物放置和移除系统
CA2987209A1 (en) *	2015-06-10	2016-12-15	Evonik Rohm Gmbh	Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer
CN107224571A (zh) *	2016-03-23	2017-10-03	张巍	一种具有坐骨神经保护功能的plga复合微球
ITUA20162094A1 (it)	2016-03-29	2017-09-29	Cid S P A	Perfezionamenti negli stent per il rilascio di principi attivi
CN105963258B (zh)	2016-04-26	2021-01-22	广州帝奇医药技术有限公司	一种缓释微粒的制备方法
KR102574993B1 (ko)	2016-05-16	2023-09-06	인타르시아 세라퓨틱스 인코포레이티드	글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
US12097292B2 (en)	2016-08-28	2024-09-24	Mapi Pharma Ltd.	Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh)	2016-08-31	2019-07-05	Mapi医药公司	包含醋酸格拉替雷的储库系统
WO2018129058A1 (en)	2017-01-03	2018-07-12	Intarcia Therapeutics, Inc.	Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
BR112019017724A2 (pt)	2017-03-26	2020-03-31	Mapi Pharma Ltd.	Sistemas depot de glatiramer para tratar formas progressivas de esclerose múltipla
CN107375910B (zh) *	2017-07-12	2020-03-24	温州医科大学附属第二医院、温州医科大学附属育英儿童医院	PTHrP在制备治疗男性性腺功能低下综合征中的应用
CN110547969A (zh) *	2019-09-03	2019-12-10	杭州诺泰澳赛诺医药技术开发有限公司	一种高比表面积纳米级缓释微粉的生产工艺及设备
IT202000017191A1 (it)	2020-07-15	2022-01-15	Xbrane Biopharma Ab	Procedimento senza acqua per preparare una composizione farmaceutica per un rilascio più prolungato e controllato di triptorelina o di un suo sale
CN112156170B (zh) *	2020-11-03	2022-10-21	北京康欣东弘医药科技有限公司	可供皮下注射的曲普瑞林缓释微球及其制备方法和用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH661206A5 (fr)	1983-09-23	1987-07-15	Debiopharm Sa	Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
CN100391445C (zh)	1996-01-24	2008-06-04	美国政府陆军部	新型的“非突发的”持续释放聚(丙交酯/乙交酯)的微球
US4897268A (en) *	1987-08-03	1990-01-30	Southern Research Institute	Drug delivery system and method of making the same
DE3734223A1 (de) *	1987-10-09	1989-04-20	Boehringer Ingelheim Kg	Implantierbares, biologisch abbaubares wirkstofffreigabesystem
US5021554A (en) *	1989-02-24	1991-06-04	Eli Lilly And Company	Process for protein particle size reduction using a fluid-energy mill
GB2246514B (en) *	1990-08-01	1993-12-15	Scras	Sustained release pharmaceutical compositions and the preparation of particles for use therein
GB9016885D0 (en) *	1990-08-01	1990-09-12	Scras	Sustained release pharmaceutical compositions
DE4041563A1 (de) *	1990-12-22	1992-06-25	Sanol Arznei Schwarz Gmbh	Verfahren zur herstellung wirkstoffhaltiger mikropartikel aus hydrolytisch abbaubaren polymeren
CH683149A5 (fr) *	1991-07-22	1994-01-31	Debio Rech Pharma Sa	Procédé pour la préparation de microsphères en matériau polymère biodégradable.
DE4223169C1 (de)	1992-07-10	1993-11-25	Ferring Arzneimittel Gmbh	Verfahren zur Mikroverkapselung wasserlöslicher Wirkstoffe
FR2693905B1 (fr)	1992-07-27	1994-09-02	Rhone Merieux	Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
JPH08505395A (ja) *	1993-01-06	1996-06-11	キナートンリミティド	生物分解性ポリエステルと生物活性ポリペプチドのイオン分子結合体
US5785976A (en) *	1993-03-05	1998-07-28	Pharmacia & Upjohn Ab	Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US6117455A (en)	1994-09-30	2000-09-12	Takeda Chemical Industries, Ltd.	Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
KR19980703876A (ko) *	1995-04-14	1998-12-05	스티븐 엘. 허스트	분산성이 개선된 분말화된 약학적 조성물
WO1996040072A2 (en) *	1995-06-07	1996-12-19	Alkermes Controlled Therapeutics, Inc.	Composition for sustained release of human growth hormone
AR012448A1 (es) *	1997-04-18	2000-10-18	Ipsen Pharma Biotech	Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada

1998
- 1998-04-16 AR ARP980101756A patent/AR012448A1/es not_active Application Discontinuation
- 1998-04-16 MY MYPI98001698A patent/MY118835A/en unknown
- 1998-04-16 TW TW087105802A patent/TW577759B/zh not_active IP Right Cessation
- 1998-04-17 RU RU99124209/14A patent/RU2198678C2/ru not_active IP Right Cessation
- 1998-04-17 BR BR9808933-1A patent/BR9808933A/pt not_active Application Discontinuation
- 1998-04-17 CZ CZ0362699A patent/CZ297078B6/cs not_active IP Right Cessation
- 1998-04-17 EP EP98921551A patent/EP0980240B1/de not_active Revoked
- 1998-04-17 JP JP54515098A patent/JP4557312B2/ja not_active Expired - Fee Related
- 1998-04-17 AT AT98921551T patent/ATE389388T1/de active
- 1998-04-17 HU HU0004297A patent/HUP0004297A2/hu unknown
- 1998-04-17 ES ES98921551T patent/ES2303353T3/es not_active Expired - Lifetime
- 1998-04-17 CN CNB031545998A patent/CN1313082C/zh not_active Expired - Fee Related
- 1998-04-17 CA CA2286575A patent/CA2286575C/fr not_active Expired - Fee Related
- 1998-04-17 DK DK98921551T patent/DK0980240T3/da active
- 1998-04-17 PL PL336296A patent/PL196771B1/pl unknown
- 1998-04-17 DE DE69839264T patent/DE69839264T2/de not_active Expired - Lifetime
- 1998-04-17 PT PT98921551T patent/PT980240E/pt unknown
- 1998-04-17 US US09/403,058 patent/US6217893B1/en not_active Expired - Lifetime
- 1998-04-17 CN CNB988052202A patent/CN1144584C/zh not_active Expired - Fee Related
- 1998-04-17 WO PCT/FR1998/000773 patent/WO1998047489A1/fr not_active Ceased
- 1998-04-17 IL IL13221798A patent/IL132217A/en not_active IP Right Cessation
- 1998-04-17 AU AU74363/98A patent/AU741964B2/en not_active Ceased
1999
- 1999-10-15 NO NO19995063A patent/NO327999B1/no not_active IP Right Cessation
2000
- 2000-11-06 US US09/707,372 patent/US6475507B1/en not_active Expired - Lifetime
2007
- 2007-07-05 AR ARP070102999A patent/AR061828A2/es not_active Application Discontinuation
2008
- 2008-02-14 NO NO20080803A patent/NO20080803L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CN1494900A (zh)	2004-05-12
CN1313082C (zh)	2007-05-02
NO327999B1 (no)	2009-11-09
AR061828A2 (es)	2008-09-24
WO1998047489A1 (fr)	1998-10-29
AU7436398A (en)	1998-11-13
US6217893B1 (en)	2001-04-17
PL336296A1 (en)	2000-06-19
DE69839264D1 (de)	2008-04-30
TW577759B (en)	2004-03-01
RU2198678C2 (ru)	2003-02-20
AR012448A1 (es)	2000-10-18
CZ362699A3 (cs)	2000-04-12
AU741964B2 (en)	2001-12-13
NO995063D0 (no)	1999-10-15
DK0980240T3 (da)	2008-07-28
BR9808933A (pt)	2000-08-01
CA2286575A1 (fr)	1998-10-29
ATE389388T1 (de)	2008-04-15
MY118835A (en)	2005-01-31
CA2286575C (fr)	2012-06-05
NO20080803L (no)	1999-11-15
CN1256628A (zh)	2000-06-14
CN1144584C (zh)	2004-04-07
US6475507B1 (en)	2002-11-05
JP2002500631A (ja)	2002-01-08
JP4557312B2 (ja)	2010-10-06
IL132217A0 (en)	2001-03-19
NO995063L (no)	1999-11-15
HUP0004297A2 (hu)	2001-08-28
DE69839264T2 (de)	2009-05-14
HK1027983A1 (en)	2001-02-02
CZ297078B6 (cs)	2006-09-13
PT980240E (pt)	2008-06-06
EP0980240B1 (de)	2008-03-19
ES2303353T3 (es)	2008-08-01
EP0980240A1 (de)	2000-02-23
PL196771B1 (pl)	2008-01-31

Legal Events

Date	Code	Title
2005-01-24	FF	Patent granted
2005-02-20	KB	Patent renewed
2008-06-05	KB	Patent renewed
2012-05-31	KB	Patent renewed
2016-03-31	KB	Patent renewed
2018-11-29	EXP	Patent expired

Publication	Publication Date	Title
AU741964B2 (en)	2001-12-13	Sustained-release compositions and method for preparing same
NL195056C (nl)	2003-07-01	Werkwijze voor het bereiden van preparaten die zouten van peptiden met op carboxy eindigende polyesters bevatten.
RU2103005C1 (ru)	1998-01-27	Фармацевтическая композиция продленного действия, используемая в ней полимерная композиция и способ ее получения
AU756148B2 (en)	2003-01-02	Pharmaceutical compositions for prolonged peptide release and preparation method
EP0904062B1 (de)	2003-07-30	Ionisches konjugat zur verzoegerten freisetzung
EP0839525B1 (de)	2004-08-04	Zubereitung mit verzögerter Freisetzung
US6630156B1 (en)	2003-10-07	Process for preparing biodegradable microspheres containing physiologically active agents
JPH07278277A (ja)	1995-10-24	生体内分解性ポリマーの末端カルボキシル基におけるエステル
JP3524195B2 (ja)	2004-05-10	徐放性製剤用基剤
MXPA99009496A (en)	2000-08-01	Sustained-release compositions and method for preparing same
HK1027983B (en)	2005-01-21	Sustained-release compositions and method for preparing same
FR2776516A1 (fr)	1999-10-01	Compositions presentant une liberation prolongee et leur procede de preparation
FR2762318A1 (fr)	1998-10-23	Compositions presentant une liberation prolongee et leur procede de preparation
HK1181681A (en)	2013-11-15	Method for the preparation of controlled release formulations